Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with diabetes, metabolic syndrome, or metabolic dyslipidemia

被引：0
|
作者：
McBride, P
Denke, MA
Pearson, T
Battisti, WP
Brady, WE
Palmisano, J
机构：
[1] Univ Wisconsin, Sch Med, Cardiovasc Dept, Madison, WI USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Kerrville, TX USA
[3] Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY USA
[4] Merck & Co Inc, Clin Dev, West Point, PA USA
来源：
DIABETOLOGIA | 2004年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
559
引用
收藏
页码：A204 / A205
页数：2
相关论文
共 50 条
  • [41] LDL-C goal attainment and cardiovascular hospitalization among CHD patients in germany
    Raiagopalan, S
    Alemao, E
    Yin, D
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 119 - 119
  • [42] LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results
    Heintjes, Edith M.
    Hirsch, Mark W.
    van der Linden, Michiel W.
    O'Donnell, John C.
    Stalenhoef, Anton F.
    Herings, Ron M. C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (08) : 2241 - 2250
  • [43] The role of small dense LDL-C/large buoyant LDL-C ratio as an independent risk factor in patients with type 2 diabetes mellitus and metabolic syndrome
    Wang, Cui
    Li, Yaoze
    Lin, Hao
    Zhu, Yulin
    Xu, Xiangdong
    Wu, PingPing
    Zhang, Yali
    Xu, Ting
    Ren, Jian
    Xu, Haibo
    Dong, Guoyu
    Xu, Yue
    Jiang, Huihui
    Zhao, Jiangman
    Zhai, Yufeng
    Peng, Pei
    Zai, Guotian
    ANNALES DE BIOLOGIE CLINIQUE, 2024, 82 (02) : 174 - 186
  • [44] Comparison of Fibrate, Ezetimibe, Low- and High-Dose Statin Therapy for the Dyslipidemia of the Metabolic Syndrome in a Mouse Model
    Paraskevas, Kosmas I.
    Pantopoulou, Alkistis
    Vlachos, Ioannis S.
    Agrogiannis, George
    Iliopoulos, Dimitrios G.
    Karatzas, Gabriel
    Tzivras, Dimitrios
    Mikhailidis, Dimitri P.
    Perrea, Despina N.
    ANGIOLOGY, 2011, 62 (02) : 144 - 154
  • [45] Combination Therapy With Lower Statin Dose and the Race to LDL-C Goal A Clear Winner?
    Ben-Yehuda, Ori
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (05) : 411 - 413
  • [46] LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO
    Nag, Soma S.
    Daniel, Gregory W.
    Bullano, Michael F.
    Kamal-Bahl, Sachin
    Sajjan, Shiva G.
    Hu, X. Henry
    Alexander, Charles
    JOURNAL OF MANAGED CARE PHARMACY, 2007, 13 (08): : 652 - 663
  • [47] RESIDUAL RISK IN SPANISH STATIN TREATED PATIENTS WITH LDL-C AT GOAL. THE DYSLIPIDEMIA INTERNATIONAL STUDY (DYSIS-SPAIN)
    Millan, J.
    Gonzalez-Juanatey, J. R.
    Alegria, E.
    Guijarro, C.
    Lozano, J. V.
    Gonzalez-Timon, B.
    Vitale, G.
    ATHEROSCLEROSIS SUPPLEMENTS, 2010, 11 (02) : 45 - 45
  • [48] Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan, Hasan
    Yetkin, Ertan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 110 (02) : 276 - 277
  • [49] Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus
    Reyes-Soffer, Gissette
    Rondon-Clavo, Carlos
    Ginsberg, Henry N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (09) : 1429 - 1438
  • [50] Impact of glycemic control on LDL-C cholesterol goal attainment in type 2 diabetes mellitus
    Isley, WL
    Reznick, L
    Weiss, TW
    Nag, SS
    Gardyn, JL
    Lu, JD
    Kovacich, D
    Alexander, CM
    DIABETES, 2001, 50 : A144 - A144
12345